-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BHPWESf+sk7b83mYsiaLzd3t2nxCGPmVA1/H4R2o6XDQ1jeDwYgWwBkwbwxNg9zE npRrDuWamq8LrICtEBj/EA== 0000950133-01-000421.txt : 20010209 0000950133-01-000421.hdr.sgml : 20010209 ACCESSION NUMBER: 0000950133-01-000421 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010208 GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH TARGET S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNSORB BIOTECH INC CENTRAL INDEX KEY: 0001025863 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-52837 FILM NUMBER: 1528914 BUSINESS ADDRESS: STREET 1: STE 201 STREET 2: 1204 KENSINGTON RD NW CITY: CALGARY ALBERTA CANA STATE: A0 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13D/A 1 w45270sc13da.txt AMENDMENT NO. 1 TO SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Synsorb Biotech Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 87160V-10-4 -------------------------- (CUSIP Number) Dr. Anders Hove, Grafenauweg 4, 6301 Zug CH/Switzerland, 011-41-41-724-5959 --------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq., Baker & McKenzie, 815 Connecticut Ave., N.W., ----------------------------------------------------------------------- Washington, DC 20006 (202) 452-7000 ----------------------------------- January 23, 2001 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 CUSIP No. 87160V-10-4 Page 2 of 5
================================================================================ 1 Name of Reporting Person: BB Biotech AG S.S. or I.R.S. Identification No. of Above Person: Not applicable: Foreign Corporation - -------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC Use Only - -------------------------------------------------------------------------------- 4 Source of Funds N/A - -------------------------------------------------------------------------------- 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------- 6 Citizenship or Place of Organization Switzerland - -------------------------------------------------------------------------------- 7 Sole Voting Power -0- - -------------------------------------------------------------------------------- 8 Shared Voting Power -0- - -------------------------------------------------------------------------------- 9 Sole Dispositive Power -0- - -------------------------------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - -------------------------------------------------------------------------------- 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] - -------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) -0- percent - -------------------------------------------------------------------------------- 14 Type of Reporting Person HC, CO - --------------------------------------------------------------------------------
SEE INSTRUCTIONS BEFORE FILLING OUT 3 CUSIP No. 87160V-10-4 Page 3 of 5
================================================================================ 1 Name of Reporting Person: Biotech Target S.A. S.S. or I.R.S. Identification No. of Above Person: Not applicable: Foreign Corporation - -------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC Use Only - -------------------------------------------------------------------------------- 4 Source of Funds N/A - -------------------------------------------------------------------------------- 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------- 6 Citizenship or Place of Organization Panama - -------------------------------------------------------------------------------- 7 Sole Voting Power -0- - -------------------------------------------------------------------------------- 8 Shared Voting Power -0- - -------------------------------------------------------------------------------- 9 Sole Dispositive Power -0- - -------------------------------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - -------------------------------------------------------------------------------- 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] - -------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) -0- percent - -------------------------------------------------------------------------------- 14 Type of Reporting Person CO - --------------------------------------------------------------------------------
SEE INSTRUCTIONS BEFORE FILLING OUT 4 CUSIP No. 87160V-10-4 Page 4 of 5 This statement hereby amends the Schedule 13D filed jointly by BB Biotech AG and Biotech Target S.A. on February 10, 1998 (as amended the "Schedule 13D"), with respect to the Common Stock, no par value (the "Common Stock"), of Synsorb Biotech, Inc. (the "Company"). Item 5. Interest in Securities of the Issuer Item 5 is hereby amended to read as follows: (a)-(b)See cover page. (c) Since January 23, 2001, Biotech Target engaged in the following transactions with respect to the Common Stock. Each of these transactions was completed on the NASDAQ stock market.
DATE TRANSACTION AMOUNT PRICE PER SHARE ------------------------------------------------------------------------ 1/23/01 Sold 200,000 $1.19 1/24/01 Sold 100,000 $1.19 1/25/01 Sold 100,000 $1.06 1/29/01 Sold 200,000 $1.12 1/30/01 Sold 100,000 $1.19 1/31/01 Sold 1,415,810 $1.12
(d) Not Applicable. (e) On January 23, 2001, BB Biotech and Biotech Target ceased to be beneficial owners of five percent or greater of the Common Stock. 5 CUSIP No. 87160V-10-4 Page 5 of 5 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: February 8, 2001 By: /s/ A. Hove Name: A. Hove Title: Signatory Authority Date: February 8, 2001 By: /s/ D. Racnjak Name: D. Racnjak Title: Signatory Authority BIOTECH TARGET, S.A. Date: February 8, 2001 By: /s/ A. Hove Name: A. Hove Title: Signatory Authority Date: February 8, 2001 By: /s/ D. Racnjak Name: D. Racnjak Title: Signatory Authority -----END PRIVACY-ENHANCED MESSAGE-----